SBFI 抑制剂重编程前列腺癌细胞的转录组景观,导致细胞死亡
Shubhra Rajput1, Joseph F LaComb2, Chris Gordon3
1Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA.
Cancers
|December 11, 2025
概括
一种新的前列腺癌 (PCa) 药物,SBFI-1143,通过诱导亡和改变基因表达,有效地阻止癌细胞生长. 这种脂肪酸结合蛋白5 (FABP5) 抑制剂显示出作为PCa.新治疗选择的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 前列腺癌 (PCa) 是男性癌症死亡的主要原因.
- 脂肪酸结合蛋白5 (FABP5) 通过脂质代谢促进PCa的进展.
- 以前的FABP5抑制剂显示出降低PCa生长的潜力.
研究的目的:
- 评估第三代FABP5抑制剂对PCa的影响.
- 评估对细胞周期,增殖,细胞亡,信号传递和转录学的影响.
主要方法:
- 使用了第三代FABP5抑制剂,包括SBFI-1143.
- 评估PCa细胞周期,增殖和细胞亡.
- 进行了RNA测序 (RNA-seq) 和基因组丰富分析 (GSEA).
主要成果:
- SBFI-1143显著抑制了PCa细胞活力,阻止了细胞周期 (G0/G1,G2/M),诱导了细胞亡,并促进了细胞死亡.
- 在抑制PCa球状体生长方面,SBFI-1143的表现优于其前身 (SBFI-103).
- 在PCa中,SBFI-1143抑制了细胞周期和染色体组织途径,调高了ER压力和亡基因,并调低了血统可塑性基因.
结论:
- SBFI-1143显著改变了前列腺癌的转录基因格局.
- SBFI-1143证明了作为前列腺癌有效治疗剂的潜力.
相关概念视频
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Experimental RNAi
7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K


